Effect of ezetimibe in hypercholesterolemic patient with glucose tolerance

Effect of ezetimibe in hypercholesterolemic patient with glucose tolerance - Effect of ezetimibe in hypercholesterolemic patient with glucose tolerance

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004091

Enrollment

150

Registered

2010-08-24

Start date

2010-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia

Interventions

After diet and exercise therapy for 12 weeks, ezetimibe(10mg) monotherapy,for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)LDL-C>120mg/dL Patients under drug therapy for dyslipidemia within 4 weeks. 2)glucose tolerance or type2 Diabetes(fasting plasma glucose>=110mg/dL or casual plasma glucos>=140mg/dL )

Exclusion criteria

Exclusion criteria: 1)HbA1c>=9% 2)Patients with a history of hypersensitivity to any ingredient of ezetimibe tablets 3)Severe renal or hepatic disease 4)Having prior myocardial infarction or stroke 5)Patients with secondary hyperlipidemia or drug-associated hyperlipidemia 6)Patients who are pregnant or nursing mothers, patients who may be pregnant, or patients who want to become pregnant during participation in the study. 7)Familial hypercholesterolemia 8)Other patients deemed not appropriate for study entry by the investigator.

Design outcomes

Primary

Measure	Time frame
The change of liipd levels(TC,TG,HDL-C,LDL-C,RLP-C)	—

Countries

Japan

Contacts

Public ContactJoe Nagakura

Chigasaki Municipal Hospital Department of Endocrinology and Metabolism

jo0806nagakura@hotmail.com0467(52)1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026